GlassScriptPhysician profile
Filomena Buncke
NPI 1306911748
$10,183.73
in general payments reported to CMS, 2019-2025
20 companies · $2,364 in 2025
The $2,364 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $2,195 · 2023: $2,940 · 2024: $2,322 · 2025: $2,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,625.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,937.97 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,266.83 | 2021-2025 | |
| Lundbeck LLC | $991.01 | 2021-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $941.90 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $940.43 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $857.05 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $580.73 | 2021-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $575.31 | 2022-2024 | Quviviq |
| Corium, LLC | $508.48 | 2022-2025 | Azstarys |
| Alkermes, INC. | $436.39 | 2022-2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $347.76 | 2023-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $199.03 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Sunovion Pharmaceuticals INC. | $142.94 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $135.79 | 2021-2023 | Spravato |
| Bausch Health US, LLC | $131.50 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $57.28 | 2023 | Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $56.59 | 2022-2024 | Fanapt, Hetlioz |
| Alfasigma USA, INC. | $38.31 | 2021 | |
| Biogen, INC. | $21.19 | 2024 | Zurzuvae |
| Neos Therapeutics, LP | $17.24 | 2025 | Exxua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Filomena Buncke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.